Abstract
A tumor surface antigen (BTA-BT20-68K) was isolated from a human mammary carcinoma cell line (BT-20). The antigen (Mr 68,000) induced the formation of high titer antibodies which recognized BTA-BT20-68K as a cell surface marker by the immune adherence hemagglutination test and recognized the soluble antigen by solid phase radioimmunoassay. The antibodies which failed to recognize human β-2-microglobulin, α-fetoprotein, and carcinoembryonic antigen were cytotoxic to the parent BT-20 tumor cells at high serum dilutions. The antibodies recognized a similar tumor surface marker isolated directly from human breast adenocarcinomas, but failed to recognize human lymphocyte antigens isolated from BT-20 cells or bound to human lymphocytes bearing human lymphocyte antigen markers in common with those of BT-20 cells. Added to BT-20 tumor cells in culture and in the absence of complement, antibody-dose-related inhibition of tumor cell growth was documented. In the presence of complement, the antibodies were highly cytotoxic to the parent cells. These results demonstrate the presence of a unique tumor surface marker with chemical and immunological properties in common with that isolated directly from human breast adenocarcinomas.
This work was supported by grants from the Clark Foundation and from the Margaret T. Biddle Foundation.